A UK multicentre audit of the management of patients with primary hypercholesterolaemia or mixed dyslipidaemia with bempedoic acid against published lipid-lowering treatment targets.

Autor:	Ramachandran S; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Maarouf A; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Mitchell K; Calderdale and Huddersfield NHS Foundation Trust, Acre Street, Lindley, Huddersfield, UK., Avades T; University Hospitals Plymouth NHS Trust, Derriford Road, Crownhill, Plymouth, Devon, UK., Smith P; Daiichi Sankyo UK Ltd, Uxbridge Business Park, Sanderson Rd, Denham, Uxbridge, UK., Boulton L; Daiichi Sankyo UK Ltd, Uxbridge Business Park, Sanderson Rd, Denham, Uxbridge, UK., Kelly J; Daiichi Sankyo UK Ltd, Uxbridge Business Park, Sanderson Rd, Denham, Uxbridge, UK., Vekaria N; Daiichi Sankyo UK Ltd, Uxbridge Business Park, Sanderson Rd, Denham, Uxbridge, UK., Hughes E; Sandwell and West Birmingham Hospitals NHS Trust, Lyndon, West Bromwich, UK.
Jazyk:	angličtina
Zdroj:	Drugs in context [Drugs Context] 2024 Aug 08; Vol. 13. Date of Electronic Publication: 2024 Aug 08 (Print Publication: 2024).
DOI:	10.7573/dic.2024-2-4
Abstrakt:	Background: Bempedoic acid, an adenosine triphosphate citrate lyase inhibitor, was introduced to UK practice via a pre-reimbursement access scheme for adults with primary hypercholesterolaemia or mixed dyslipidaemia who are at high risk of cardiovascular disease, in whom statins are either not tolerated or contraindicated, who have not achieved target cholesterol, despite being on ezetimibe therapy, and do not qualify for PCSK9 inhibitor treatment. This retrospective multicentre audit aimed to evaluate the achievement of lipid-lowering targets with bempedoic acid in UK patients based on recommendations in the Joint British Societies (JBS) guidelines for the prevention of cardiovascular disease. Methods: Pseudo-anonymized medical record data for 221 adults treated with bempedoic acid as part of the UK scheme were entered into a bespoke data collection tool at four UK hospitals. Patient demographics, clinical characteristics, treatment pathways and lipid assessment results (against JBS lipid-lowering targets) were collected against pre-specified criteria. Results: Overall, 54% (99/184) of patients achieved the JBS2 audit standard (total cholesterol (TC) <5 mmol/L and low-density lipoprotein cholesterol (LDL-C) <3 mmol/L or ≥25% reduction in TC and ≥30% reduction in LDL-C) at 12 weeks post-initiation. At week 12, the mean absolute change in LDL-C was -1.0 mmol/L; the mean percentage reduction from baseline was 22.0%. Additionally, 52% (96/185) of patients had an LDL-C of <3 mmol/L and 10% (18/185) an LDL-C of <1.8 mmol/L at 12 weeks (as per JBS3). Conclusion: This audit highlights the role of bempedoic acid as part of combination therapy for a population with previously limited treatment options. Competing Interests: Disclosure and potential conflicts of interest: SR has received research grants, travel grants and speakers’ honoraria from Besins Healthcare, Daiichi Sankyo, Novartis, and Amarin. EH is a trustee of HEARTUK and Dinwoodie Charity, received payment from Daiichi Sankyo UK Ltd., Amarin, Amgen, ACCEA and Novartis, and received funding from Sanofi and Amarin. TA has received funding and honoraria from Daiichi Sankyo UK Ltd. PS is an employee of Daiichi Sankyo UK Ltd. LB, NV and JK are former employees of Daiichi Sankyo UK Ltd. AM and KM have no conflicts of interest to declare. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2024/07/dic.2024-2-4-COI.pdf (Copyright © 2024 Ramachandran S, Maarouf A, Mitchell K, Avades T, Smith P, Boulton L, Kelly J, Vekaria N, Hughes E.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu